SynthesisFrontiers in cardiovascular medicine2026
Efficacy and safety of different antithrombotic treatment regimens in patients undergoing transcatheter mitral valve repair and atrial fibrillation; A meta-analysis and systematic review.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimal antithrombotic therapy following transcatheter mitral valve repair (TMVR/TEER) in patients with atrial fibrillation remains uncertain, with substantial practice variation and reliance on nonrandomized data. Methods: We performed a systematic review and network meta-analysis of observational studies evaluating antithrombotic strategies after TMVR/TEER with atrial fibrillation. Antithrombotic regimens were harmonized into two main categories: oral anticoagulation [OAC; including vitamin K antagonists [VKAs] and direct oral anticoagulants [DOACs]] and antiplatelet therapy (APT; including aspirin or clopidogrel, alone or in combination). Outcomes of interest were ischemic stroke, major bleeding, and all-cause mortality. Pairwise and network random-effects models were applied to derive odds ratios (ORs) with 95% confidence intervals (CIs). Results: Four multicenter observational cohorts ( Conclusions: In patients undergoing TMVR/TEER with atrial fibrillation, OAC strategies appeared to be associated with lower bleeding risk and potentially favorable mortality outcomes compared with antiplatelet therapy. However, conclusions regarding comparative efficacy, particularly for stroke prevention, should be interpreted cautiously due to the limited number of studies and the observational nature of the available evidence. Thus, the evidence base remains limited by observational design, heterogeneous comparators, and inconsistent outcome definitions. Randomized trials are urgently needed to guide antithrombotic management in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.